



May 6, 2025

Re: Section 232 Investigation into Imports of Pharmaceuticals and Related Products

The Arizona Chamber of Commerce & Industry and the Arizona Manufacturers Council (AMC) strongly urge the Department of Commerce to reject any proposed tariffs on imported pharmaceuticals and related products as part of the ongoing Section 232 investigation.

As a statewide business advocacy organization representing employers across all sectors, we recognize the critical role that access to affordable, reliable medical products plays in maintaining a healthy workforce and driving continued economic growth.

Arizona is home to a growing bioscience sector, and we have made strategic investments in life sciences, health care, and innovation. A sudden imposition of tariffs would undermine those efforts — increasing costs, straining supply chains, and potentially worsening shortages of essential medications.

We support lifesaving drug innovation. We oppose policies that would make these treatments harder to access. Tariffs on critical pharmaceuticals will make lifesaving and life-changing drugs more expensive, reduce availability, and ultimately harm patients. These costs won't just be absorbed by manufacturers — they'll be passed on to families, providers, and employers.

These tariffs risk weakening our health care system and limiting access to treatments for patients who need them most. We've already seen the devastating impact of pharmaceutical shortages. Burdening the supply chain further will only force providers to make impossible decisions and reduce quality of care — with direct consequences for patients, health systems, and employers alike.

Tariffs of this nature also send the wrong message to global manufacturers. At a time when we should be encouraging domestic investment, predictable trade policy, and supply chain resilience, this action would inject new uncertainty into an already fragile system.

The Arizona Chamber and the AMC urge the Department to prioritize supply chain stability and reject measures that would restrict access, increase costs, and hinder medical innovation.

Respectfully,

A handwritten signature in black ink, appearing to read "Danny Seiden".

Danny Seiden
President and CEO
Arizona Chamber of Commerce & Industry